3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pain
7
Neoplasms
3
Pain, Postoperative
2
Cancer Pain
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Substance Withdrawal Syndrome
1
Sezary Syndrome
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Interventions
Morphine
1
Ketamine
1
Chitosan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Cancer: Breakthrough Pain
×
Morphine
×
Clear all
NCT02591017
2018-11-13
ONKEMI
University Hospital, Basel, Switzerland
Phase 3
Terminated
11 enrolled